Interstitial Nephritis from Mesalazine: Case Report and Literature Review

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 2004 Mar 10

PMID 15007714

Citations 21

Authors

Lois J Arend

James E Springate

Affiliations

Soon will be listed here.

Abstract

We report a new case of biopsy-confirmed mesalazine-induced interstitial nephritis in an 18-year-old male with ulcerative colitis. His renal function improved with drug discontinuation and corticosteroid treatment. An English literature review revealed an additional 22 cases of this complication that, taken together, showed (1) a male predominance, (2) an absence of specific symptoms or findings on urinalysis, (3) a 61% frequency of residual chronic renal insufficiency with 13% of patients developing end-stage renal disease, and (4) an apparent favorable response to steroid therapy. We conclude that patients receiving 5-aminosalicylates should be routinely monitored with serum creatinine measurements to prevent this uncommon but potentially serious adverse drug reaction.

Citing Articles

Insights into renal and urological complications of inflammatory bowel disease.

Singh A, Khanna T, Mahendru D, Kahlon J, Kumar V, Sohal A World J Nephrol. 2024; 13(3):96574.

PMID: 39351187 PMC: 11439091. DOI: 10.5527/wjn.v13.i3.96574.

Kidney Diseases Associated With Inflammatory Bowel Disease: Impact of Chronic Histologic Damage, Treatments, and Outcomes.

Yandian F, Caravaca-Fontan F, Herrera Hernandez L, Soler M, Sethi S, Fervenza F Kidney Int Rep. 2024; 9(2):383-394.

PMID: 38344742 PMC: 10851004. DOI: 10.1016/j.ekir.2023.11.011.

Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic Era.

Dincer M, Toker Dincer Z, Bakkaloglu O, Yalin S, Trabulus S, Celik A Med Sci Monit. 2022; 28:e936497.

PMID: 35791280 PMC: 9272730. DOI: 10.12659/MSM.936497.

A Case Report and Literature Review of Mesalazine-Induced Kidney Injury in a Pediatric Patient With Ulcerative Colitis.

Wang S, Zhou P, Li Z Front Pediatr. 2022; 10:808472.

PMID: 35615637 PMC: 9125087. DOI: 10.3389/fped.2022.808472.

5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review.

Moss J, Parry C, Holt R, McWilliam S Eur J Med Res. 2022; 27(1):61.

PMID: 35488310 PMC: 9052675. DOI: 10.1186/s40001-022-00687-y.

References

Calvino J, Romero R, Pintos E, Losada E, Novoa D, Guimil D . Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. Clin Nephrol. 1998; 49(4):265-7. View

Riley S, Lloyd D, Mani V . Tests of renal function in patients with quiescent colitis: effects of drug treatment. Gut. 1992; 33(10):1348-52. PMC: 1379602. DOI: 10.1136/gut.33.10.1348. View

Calder I, Funder C, Green C, Ham K, Tange J . Nephrotoxic lesions from 5-aminosalicylic Acid. Br Med J. 2010; 1(5793):152-4. PMC: 1787127. DOI: 10.1136/bmj.1.5793.152. View

World M, Stevens P, Ashton M, Rainford D . Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant. 1996; 11(4):614-21. DOI: 10.1093/oxfordjournals.ndt.a027349. View

Howard G, Lynn K . Renal dysfunction and the treatment of inflammatory bowel disease (IBD): a case for monitoring. Aust N Z J Med. 1998; 28(3):346. DOI: 10.1111/j.1445-5994.1998.tb01962.x. View

Wilcox G, Reynolds J, GALVANEK E . Nephrotoxicity associated with olsalazine. Am J Med. 1996; 100(2):238-40. DOI: 10.1016/s0002-9343(97)89466-1. View

Corrigan G, Stevens P . Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2000; 14(1):1-6. DOI: 10.1046/j.1365-2036.2000.00683.x. View

Hamling J, Raedler A, Helmchen U, Schreiber S . 5-Aminosalicylic acid-associated renal tubular acidosis with decreased renal function in Crohn's disease. Digestion. 1997; 58(3):304-7. DOI: 10.1159/000201459. View

Frandsen N, Saugmann S, Marcussen N . Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Nephron. 2002; 92(1):200-2. DOI: 10.1159/000064461. View

10.

De Broe M, Stolear J, Nouwen E, Elseviers M . 5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?. Nephrol Dial Transplant. 1997; 12(9):1839-41. DOI: 10.1093/ndt/12.9.1839. View

11.

Diener U, Tuczek H, Fischer C, Maier K, Klotz U . Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn Schmiedebergs Arch Pharmacol. 1984; 326(3):278-82. DOI: 10.1007/BF00505331. View

12.

Fockens P, Mulder C, Tytgat G, Blok P, Ferwerda J, Meuwissen S . Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol. 1995; 7(11):1025-30. DOI: 10.1097/00042737-199511000-00003. View

13.

Margetts P, Churchill D, Alexopoulou I . Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine. J Clin Gastroenterol. 2001; 32(2):176-8. DOI: 10.1097/00004836-200102000-00019. View

14.

Walker A, Szneke P, Bianchi L, Field L, Sutherland L, Dreyer N . 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Am J Gastroenterol. 1997; 92(5):816-20. View

15.

Witte T, Olbricht C, Koch K . Interstitial nephritis associated with 5-aminosalicylic acid. Nephron. 1994; 67(4):481-2. DOI: 10.1159/000188024. View

16.

Mahmud N, OToole D, OHare N, Freyne P, Weir D, Kelleher D . Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment Pharmacol Ther. 2002; 16(2):207-15. DOI: 10.1046/j.1365-2036.2002.01155.x. View

17.

Ransford R, Langman M . Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002; 51(4):536-9. PMC: 1773410. DOI: 10.1136/gut.51.4.536. View

18.

Behrens R, Ruder H . [Chronic inflammatory intestinal disease and nephritis]. Klin Padiatr. 1992; 204(1):61-4. DOI: 10.1055/s-2007-1025324. View

19.

Izzedine H, Simon J, Piette A, Lucsko M, Baumelou A, Charitanski D . Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology. 2002; 123(5):1436-40. DOI: 10.1053/gast.2002.36613. View

20.

Berryman E, Zerouala A, Meschter C, Spenard J . Intrarectal administration of 5-aminosalicylic acid to rabbits and dogs. Hum Exp Toxicol. 2002; 21(3):159-63. DOI: 10.1191/0960327102ht236oa. View